Member Info for KUMS

Nicely.

@ 8.01p!

Nice to here from you. Yes I am in here. When this dropped to 3p I got back in.

now!

to 5.9% so not sold all! Poss will back back & more now after results yesterday! NT or in Auction now!

I meant! Too early 4 me to type.

in Sept I believe.

had article on OXB & so had The Times last Friday. Both article mentioned that Rodman & Renshaw, the investment bank in New York, predicts a positive outcome for CTL019 FDA’s Advisory Committee.

now

now

@ 10.25 & buys 10.50. It was excellent opp last week to top up near 9.30/9.40. All that money from Novartis & Royalties should start seeing this moving to 11p+

The market for the drug is for the whole world! Not just USA! People are waking up to this!

now @ 9.70/9.75p Added more today @ 9.40.

yesterday did not come up on LSE. So even Aviva are now in here. EVeryone is very upbeat about the USA approval. Stephan Grupp is the person in charge of the trials in Pennsylvania. Stephan A. Grupp, MD, PhD, is Director of the Cancer Immunotherapy Program, director of Translational Research for the Center for Childhood Cancer Research at CHOP and medical director of the Stem Cell Laboratory. Areas of Expertise: Development of engineered T cell therapies such as CTL019, Novel leukemia therapy, Stem cell transplants, Treatment of high-risk neuroblastoma. Trails haveshown that the drug can change lives of children as we have seen the reporting in major newpaper & medical journals. He is very upbeat about this. So as always it's risk/reward. At 3 p, everyone had a chance to gain more and loose less. At 9p balance has shiffted a bit. Then again there could be a take off in sp if approval is granted. For me, I want to be in, inside 10p! Making your mind up time is now. Good Luck.

this morning. Aviva & it's subsidaries have a holding in OXB.

Oxford BioMedica gets lift from $100m Novartis deal http://www.standard.co.uk/business/market-report-oxford-biomedica-gets-lift-from-100m-novartis-deal-a3581516.html More reports shold follow in Daily papers tomorrow. Next week: A key meeting takes place next week with the FDA, which could pave the way for the treatment to become the first gene therapy to be given the green light in the US.

10.50p

watch on this. I have seen discussion on this from Indian Doctors inIndia. So I can imagine this been discussed in many other parts of the world as it is a life changing drug!

Under the terms of the agreement which includes minimum offtake requirements, Oxford BioMedica could potentially receive in excess of $100 million from Novartis over the next three years. This amount includes a $10 million upfront payment, various performance incentives and bioprocessing and development services. The supply agreement is for three years, extendable to five years subject to the agreement of both parties. BRILL!

were quick to pick up stock @ 9.50 etseq. Now buys over 10p. Part & parcel of trading & very good to see stock cleared & bought by new investors. Those who picked up @ 9.50 in profit altready.